The latest studies have shown that 1-MNA reduces substantially pulmonary fibrosis and has anti-inflammatory effects.
In a model of pulmonary fibrosis induced by bleomycin, it was demonstrated that 1-MNA reduced pulmonary fibrosis by 28%. In this model, 1-MNA was more effective than reference drugs (nintedanib and fluticasone).
At the same time, in the tested model, 1-MNA provided a statistically significant reduction in the eosinophil count compared to the control group. Eosinophils are a type of white blood cells that increase in, for example, allergic diseases but also during viral and bacterial diseases. Among other things, eosinophils produce transforming growth factor beta (TGF-β), which participates in the pulmonary fibrosis process (Figure A).
In the same model of pulmonary fibrosis induced by bleomycin, 1-MNA caused a statistically significant reduction in the C-reactive protein level.
Figure A. Diagram illustrating the role of TGF-β in the pathogenesis of idiopathic pulmonary fibrosis.